All In Biotech

Drug Trial Radar · NCT01953926

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

582

Actual

Start

Sep 30, 2013

Primary completion

Jan 2, 2023

Study completion Jan 2, 2023

Sponsor

Lead sponsor
Puma Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Oct 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.

Conditions

  • Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Interventions

  • NeratinibDrug

    240 mg administered orally, once daily with food, continuously in 28 day cycles

  • FulvestrantDrug

    500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle

  • TrastuzumabDrug

    Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter

  • PaclitaxelDrug

    80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) by Independent Central Review (Breast Cancer With Prior CDK46i Cohort)Time frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 58 months
  2. Confirmed Objective Response Rate (ORR) by Investigator Review (Cervical Cancer Cohort)Time frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 58 months
  3. Objective Response Rate (ORR) at First Assessment by Investigator Review (All Other Cohorts)Time frame: From first treatment date to first Complete or Partial Response, whichever came earlier, assessed up to 8 or 9 weeks

Locations

60 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • University of California, San Diego

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Kaiser Permanente NoCal (STRATA)

    Vallejo, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Metro Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota

  • Washington University

    St Louis, Missouri

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • UPMC Magee-Woman's Hospital, Women's Cancer Center

    Pittsburgh, Pennsylvania

  • Saint Francis Cancer Center-Bon Secours

    Greenville, South Carolina

  • The West Clinic

    Germantown, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Gundersen Center for Cancer and Blood Disorders

    La Crosse, Wisconsin

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Peter MacCallum Cancer Centre

    East Melbourne, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • British Columbia Cancer Center

    Vancouver, British Columbia, Canada

  • University Hospital, Rigshospitalet

    Copenhagen, Denmark

  • Institut Bergonié

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • Institut Curie - Hopital Rene Huguenin

    Saint-Cloud, Île-de-France Region, France

  • Institut Gustave Roussy

    Villejuif, Paris, France

  • St. Vincent's University Hospital

    Dublin, Leinster, Ireland

  • Hadassah Medical Center

    Jerusalem, Israel

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.